01—Abstract
Summary
Summary of the 10-K filed March 18, 2013. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated, a biopharmaceutical company focused on inhaled therapies for serious lung diseases, reported no revenue for 2012 and a net loss of $41.4 milliona ($1.56 per share), compared with a net loss of $68.8 million ($2.95 per share) in 2011, which included a $26.0 million impairment loss.
Its lead candidate, ARIKACE (liposomal amikacin for inhalation), is in a phase 3 trial in cystic fibrosis patients with Pseudomonas lung infections in Europe and Canada, with clinical results expected in mid-2013, and in a phase 2 trial in non-tuberculous mycobacteria (NTM) lung infections, with results expected in Q4 2013. The company cites its own estimate of roughly $1 billionb in combined global market potential for the two orphan indications. As of December 31, 2012, cash, cash equivalents and a certificate of deposit totaled $92.9 million, and the company stated it believes it has sufficient funds for 2013, though it has no committed sources of capital beyond that.
The filing also flags significant risks. The FDA objected to the ARIKACE trade name in early 2013, and the company has not decided whether to appeal. A rat carcinogenicity finding led to a 2011 clinical hold, since lifted, and a 9-month dog inhalation toxicity study was completed in January 2013 with an unaudited interim report submitted to the FDA.
Management concluded that internal control over financial reporting was ineffective as of December 31, 2012, due to a material weakness in administering the 2000 Stock Incentive Plan, after equity awards exceeded per-person sub-limits. The company also faces a possible Nasdaq listing rule violation and shareholder demands related to those grants, and it has a $20.0 millionc secured loan with Hercules Technology Growth Capital.
02—Key points
Key Highlights
- No revenue in 2012, versus $4.4 million in 2011 and $6.9 million in 2010; net loss narrowed to $41.4 million from $68.8 million attributable to common stockholders.
- Operating expenses were $42.4 million in 2012, with R&D of $29.8 million and G&A of $12.7 million.
- Accumulated deficit reached $335.5 million at December 31, 2012; the company has never declared or paid cash dividends.
- ARIKACE phase 3 CF trial (Europe and Canada, 302 patients) fully enrolled in November 2012 with results expected mid-2013; NTM phase 2 trial results expected Q4 2013.
- Cash, cash equivalents and certificate of deposit of $92.9 million at year-end 2012, after $25.7 million from a common stock offering and $20.0 million in debt financing.
- FDA objected to the ARIKACE trade name in early 2013; the company has not decided whether to appeal and may need an alternative name.
- Management identified a material weakness in controls over the 2000 Stock Incentive Plan, and Ernst & Young issued an adverse opinion on internal control over financial reporting.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2012filed March 18, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $0$4.42M | −100.0% |
| R&D Expenses | $29.78M$28.62M | +4.0% |
| Operating Expenses | $42.44M$66.14M | −35.8% |
| Operating Income | -$42.44M-$61.72M | +31.2% |
| Interest Expense | $763K$10K | +7530.0% |
| Net Income | -$41.37M-$59.66M | +30.7% |
| EPS (Basic) | $-1.56$-2.95 | +47.1% |
| Shares Outstanding (Basic) | 26.55M23.35M | +13.7% |
| Shares Outstanding (Diluted) | 26.55M23.35M | +13.7% |
05—Questions
Frequently Asked Questions
What is the company's lead product candidate and what indications is it being developed for?
The lead candidate is ARIKACE (liposomal amikacin for inhalation), a once-daily inhaled antibiotic. It is in clinical trials for two orphan indications: a phase 3 trial in cystic fibrosis patients with Pseudomonas aeruginosa lung infections, and a phase 2 trial in patients with non-tuberculous mycobacteria (NTM) lung infections. The company also says it has granted orphan drug designation in Europe and the US for the CF indication.
Does Insmed generate revenue, and how did its losses change in 2012?
Insmed recognized no revenue in 2012, compared with $4.4 million in 2011. The net loss attributable to common stockholders was $41.4 million ($1.56 per share) in 2012, down from $68.8 million ($2.95 per share) in 2011, which included a $26.0 million impairment loss and a $9.2 million beneficial conversion charge.
What are the key near-term catalysts and risks for ARIKACE?
Near-term catalysts include CF phase 3 results expected in mid-2013 and NTM phase 2 results expected in Q4 2013. Key risks include the FDA's objection to the ARIKACE trade name, the rat carcinogenicity finding that led to a clinical hold (lifted in 2012), the ongoing dog toxicity study, reliance on single-source suppliers PARI and Althea, and the company's stated uncertainty about whether it will pursue a US CF trial.
Is the company well funded?
As of December 31, 2012, the company had $92.9 million of cash, cash equivalents and a certificate of deposit, and management stated it believes it has sufficient funds to meet its financial needs for 2013. The filing also says the company had no committed sources of capital and may need additional financing, which could dilute existing shareholders.
What control and governance issues did the company disclose?
The company disclosed a material weakness in internal control over the administration of its 2000 Stock Incentive Plan, after it inadvertently granted awards exceeding per-person annual sub-limits. It notified Nasdaq, which may conclude that securities were issued without shareholder approval in violation of Nasdaq Listing Rule 5635(c). A shareholder demand letter was also received, and the board has proposed a remediation plan that conditions vesting of excess awards on shareholder approval.
06—Continue